p53 peptides for cancer vaccines

The

d exlr~e ua~ matrix tsrnpener~s may shed the tras s4 5sam r e ~ i o n try 9s-ehe#; n~muse s!#stemo Although the ~ork is n iS ea~ est slage4~ ths te ~o# t~e of ~ts s; it S to. ~t ~ eo@d be ~/t~ ~m a c4 human ceII& ~

R@

Rss~s. M d ~ e Oenle Vidcd~ ~ o ~ a . E~t Gd , UK AHI9 38Z.

#53 ptides for vacctReS Tar~i~ ~ a ~

as a ~

tumor

, M. e t £ (t995}

T

C~otoxic T I,S~ CTLs} can mcsgnize a~8 ~II turnout ~4}s a~4~as , tSsy are o tire ~ts~or ¢:as~ CTLs tze to me}or h~e* @mpaibiiity c o ~ e x (MHC} c~ass i ~es expressed on the suffa~ d the t est~ and much effo~ has ~ e n devoted to @fining the~x9 on, ~t~s f~ a~4

au~t£s c ~osm,&s~ste;tthe pros ¢~md toe ~o p53 n humans by usng race ~ d e tanager:, c ~er the @mm@~ hum.ar~tIHC typ~ !d!M.A2 t ,,Tlses~ mc~ a e~. the ~4'e!o~ment n dvo o~ mur#~e Cibs that a@ ~c o~' @s ~undS t,'o the M,HC me~£~.~le HLAoA2~to ~&nv hu~r~ s p53 i ~ @~ar hs ffem the" msdns , so mu~ ~w~CTLs ~amst the %re~§r~ d %e p53 pre~in ~ e y w~sn m~e ~ : e i ed W tkle @3 p eso s~9 S f@m p63 were ~ @@d @kSt~sdne CTLs @b te tee.,. ~aize a ~adety d human c8~ ~i~es~ t ~et T e ant~sen~o r'~g tutus and the %~4; ~q~e mc ~ e , a:qdh u ~ s a~e nay 5>s41a;ft,~ta~ ~df~t@d is the mice t~ useM t%r the des ant of imm~t~a~apy is hu , It emaSns to be rn ~sd ,a%e/:f'e~ human CTLs can b.e g.~nerated against t ~53 ~sd wt T @~S wi!l and . %%e d ~s t¢>at~ n ~q the '}ca @ *~e ~ e ~ n t ~sma,n p5S @eLs, tShe CTLs stit~ used as a d To@I~ (TCR} fer into ~xsman T o This sy iS a t~@to ~4ine for us~ is oanx@~v~enes~ and TCRs ca of p53 arid ~ e f human p e o reins ~art~ACy e @3 tumeure.,

Rx@a5 U ty sh: FeSbw. ~r~t of ~e "Te~sovts5Buiidng Univ~ty of 'We!asC@Sseed Us4ic ne U ~ CF4 4XX.

Pa~x

t~terature

cur ant v@ and ~os~v~,a gene,.de i,ve9 Ws e~s:s W©~k a~'j! ~OW ?"!ey car be u~sS/s vyo ~{}~~aS@ o tanseqt t~ansdueten {/human @ s Many goups have fe}c~tsd t!~e 'xa~sse~ of DNA to @ oa~o#~cu~e~s e~

e¢ u me,, Th~s ~at W ng ~ o ~,smvi~ a s ~nc~e~ ~q the re@on ~Iio ef HeLa 8s!ls ~ y b e £n ~s~ li @ w e 9 @ a §ere n§ 5oga~ e was only efii~ cent ~;~e ion of sal to See ~& R~x ~ed ta a deseo @@ ~cresee n S' : £ rise ~ses~ ~mst I of ceils cau~d be ° @ the fou~ ~4erent fotmu exam ned n @s bined wit~ tsande~r n was the ~ s t imp~essiveoThe 5°§a ~ase a~ivity ~es@£i@ from t@nsfer of tse gere in{o ~Xse@~ts that wee of ~e ~ L a ce4s; to ne IeveS s.~e~ six p .~ m~k%; t~ansient ssion d a nono,,i~eg ~,~A The ~arme@anBm d W this new~, h ~ e r ns uncbsq S~t ~he ~a, ~t~Aa~ d t~s w$ when s @se~ t~ss t@nsfemn a~'e ~ For exm~o~e a @ttr csutd ~s u ~ 4 to target a ,~. W ca4/ty#e, or a ~ /i§and ooukt ~ used to ~edu~se~e host mmune S~the t~sfe~ co x s~d increase t~an¢'ef scy. A t~a n efficiency hing t@% is a sight.ant W a n @ in gene t~n@er ~hnobSW; the will thus e~eu~a@e these ~od~.ng on

into s ~ a~

of tt°e

B

at

r~st huma~ ca:s, ~ R

Liposomes gene therapy

Rsan

r~s. ~

a~S

~#ematme........................................................................................... ~ ir

~@a of p53 ~ that ~at tis~e ~,3, ~ a ~er ~evel, a£4 ~ e of the ~ t is ~i~y to ~ e ~ ' ~ R;g e r ~ N ~ aa te ~e t~moar Evea if v a ~ ~s &~ is ,an tothe s~ d

This egy for overe~mi~ ~ e

d

~ ~ ~ese

C

, poW° ( 1 ~ }

.................................................................................

T ~ eady @k~# ~ e

yet to ~

s~rato . T~

th~ ~efe ~ @ 8 ~ n d @he techo thee can ge~a transf~ ~]t r t ~ to m

147 Cc~ydghl © l ~

E~vier S @ e ~ Lid, All r;@~s re'.~/e& ~357 ~43H~.~lS~5.ft(}